Antigen-Specific Detection of Autoantibodies Against Myeloperoxidase (MPO) and Proteinase 3 (PR3)

Vanderlocht, Joris; Beers, Joyce J B C van; Limburg, P. C.; Damoiseaux, Jan; Roozendaal, Caroline

doi:10.1007/978-1-4939-8949-2_12

Cited by 4 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hand-out is primarily focused on commercially available assays for clinical purposes. For inhouse assays there exist detailed protocols (13,27), but they require a more extended validation, which is beyond the scope of the current paper. Important items for the laboratory evaluation are reproducibility (intra-and inter-assay variability), carry-over in analyzers, and linearity (vide supra).…”

Section: Implementation Of Anca Assays In Clinical Practicementioning

confidence: 99%

ANCA Testing in Clinical Practice: From Implementation to Quality Control and Harmonization

Damoiseaux

2021

Front. Immunol.

View full text Add to dashboard Cite

Analyses for the presence of anti-neutrophil cytoplasmic antibodies (ANCA) are important in the diagnostic work-up of patients with small vessel vasculitis. Since current immuno-assays are predominantly designed for diagnosis of patients with ANCA-associated vasculitis (AAV), implementation in routine clinical practice, internal and external quality control, and harmonization are focused on this particular use. However, ANCA testing may also be relevant for monitoring therapy efficacy and for predicting a clinical relapse in AAV patients, and even for diagnostic purposes in other clinical situations. In the current review, the topics of implementation, quality control, and standardization vs. harmonization are discussed while taking into account the different applications of the ANCA assays in the context of AAV.

show abstract

Section: Implementation Of Anca Assays In Clinical Practicementioning

confidence: 99%

ANCA Testing in Clinical Practice: From Implementation to Quality Control and Harmonization

Damoiseaux

2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Solid phase immunoassays, e.g. enzyme-linked immunosorbent assay (ELISA), fluoro-enzyme immunoassay, chemiluminescence immunoassay, laser bead immunoassay, dot/line blot, are used for detection of specific antibodies to proteinase-3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA) [6]. The antigens (PR3 or MPO) can be directly attached to the solid phase or indirectly, either through a monoclonal capture antibody or through a smaller anchor molecule (e.g.…”

mentioning

confidence: 99%

2020 international consensus on ANCA testing beyond systemic vasculitis

Moiseev

Tervaert

Arimura

et al. 2020

Autoimmunity Reviews

100

View full text Add to dashboard Cite

This document follows up on a 2017 revised international consensus on antineutrophil cytoplasm antibodies (ANCA) testing in granulomatosis with polyangiitis and microscopic polyangiitis and focuses on the clinical and diagnostic value of ANCA detection in patients with connective tissue diseases, idiopathic interstitial pneumonia, autoimmune liver diseases, inflammatory bowel diseases, anti-glomerular basement membrane (GBM) disease, infections, malignancy, and during drug treatment. Current evidence suggests that in certain settings beyond systemic vasculitis, ANCA may have clinical, pathogenic and/or diagnostic relevance.Antigen-specific ANCA targeting proteinase-3 and myeloperoxidase should be tested by solid phase immunoassays in any patient with clinical features suggesting ANCAassociated vasculitis and in all patients with anti-GBM disease, idiopathic interstitial pneumonia, and infective endocarditis associated with nephritis, whereas in patients with other aforementioned disorders routine ANCA testing is not recommended. Among patients with autoimmune liver diseases or inflammatory bowel diseases, ANCA testing may be justified in patients with suspected autoimmune hepatitis type 1 who do not have conventional autoantibodies or in case of diagnostic uncertainty to discriminate ulcerative colitis from Crohn's disease. In these cases, ANCA should be tested by indirect immunofluorescence as the target antigens are not yet well characterized. Many questions concerning the optimal use of ANCA testing in patients without ANCA-associated vasculitis remain to be answered.Testing for anti-neutrophil cytoplasm antibodies (ANCA) directed towards proteinase 3 (PR3) and myeloperoxidase (MPO) is commonly performed to support the diagnosis of ANCA-associated vasculitides (AAV) that encompasses granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). In 2017, a revised international consensus on testing of ANCA in GPA and MPA was proposed [1]. This consensus document focused on ANCA testing in AAV and briefly described other conditions that were reported to be associated with ANCA positivity, mostly in the context of the differential diagnosis of other inflammatory diseases [2]. The current document is a follow-up on the previous consensus statements [1,3,4] and highlights the clinical and diagnostic value of ANCA testing in patients with various autoimmune, infectious and neoplastic diseases. However, the number of high quality studies addressing this issue is limited, and many unresolved issues concerning the optimal use of ANCA testing in non-AAV remain to be elucidated. MethodsThis Consensus Statement was prepared by a group of experts based on the results of a comprehensive search in PubMed for disorders that can be associated with ANCApositivity, by using a variety of search terms, and all relevant available literature was critical reviewed. Additional publications were identified in the references of the available articles. The resulting manus...

show abstract

Integrated Low Cost Optical Biosensor for High Resolution Sensing of Myeloperoxidase (MPO) Activity Through Carbon Nanotube Degradation

Nandeshwar

Tallur

2021

IEEE Sensors J.

View full text Add to dashboard Cite

Antigen-Specific Detection of Autoantibodies Against Myeloperoxidase (MPO) and Proteinase 3 (PR3)

Cited by 4 publications

References 45 publications

ANCA Testing in Clinical Practice: From Implementation to Quality Control and Harmonization

ANCA Testing in Clinical Practice: From Implementation to Quality Control and Harmonization

2020 international consensus on ANCA testing beyond systemic vasculitis

Integrated Low Cost Optical Biosensor for High Resolution Sensing of Myeloperoxidase (MPO) Activity Through Carbon Nanotube Degradation

Contact Info

Product

Resources

About